Unknown

Dataset Information

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.


ABSTRACT:

Background

Tocilizumab (TCZ), an interleukin-6 receptor antibody, has previously been used for treating patients with the coronavirus disease 2019 (COVID-19), but there is a lack of data regarding the administration timing of TCZ.

Objectives

This study aimed to evaluate the timing and efficacy of TCZ in the treatment of patients with COVID-19.

Methods

Laboratory-confirmed patients with COVID-19 with an elevated interleukin-6 (IL-6) level (>10 pg/ml) were offered TCZ intravenously for compassionate use. Clinical characteristics, laboratory tests, and chest imaging before and after the administration of TCZ were retrospectively analyzed.

Results

A total of 58 consecutive patients who met the inclusion criteria and with no compliance to the exclusion criteria were

SUBMITTER: Li P 

PROVIDER: S-EPMC8084410 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature